AL16431.1 is Identified As a Biomarker for Bladder Cancer Progression and Immunotherapy Response

Overview

Journal Sci Rep

Specialty Science

Date 2025 Jan 8

PMID 39774770

Authors

Sihao Zhang

Yaxuan Wang

Zhenwei Han

Baosai Lu

Kexin Sun

Zhihai Teng

Chenggen Jin

Fang Li

Hao Yuan

Fengran Guo

Yanping Zhang

Affiliations

Soon will be listed here.

Abstract

LncRNA AL161431.1 is currently known as a factor that can promote epithelial-mesenchymal transition. However, its role in the prognosis, immune infiltration and progression of bladder cancer (BLCA)patients is still unclear. The expression of AL161431.1 is elevated in BLCA tissues compared to normal tissues according to the TCGA database. By combining this data with clinical information, patients with high AL161431.1 expression have more advanced clinicopathological stages and shorter survival periods. Furthermore, AL161431.1 was identified as an independent prognostic factor for bladder cancer. We further analyzed the differences in immune infiltration, tumor mutation burden (TMB), immune checkpoints, and sensitivity to immunotherapy between groups with different levels of AL161431.1 expression. Enrichment analysis demonstrated that AL161431.1 is associated with numerous immune signaling pathways. High expression of AL161431.1 in cancer tissues was confirmed by qRT-PCR. CCK8, transwell, and wound healing demonstrated the oncogenic effects of AL161431.1. In conclusion, AL161431.1 is associated with immune infiltration in bladder cancer and has the potential to become a biomarker for predicting the prognosis of BLCA.

References

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Lee J, Lee M, Garon E, Goldman J, Salehi-Rad R, Baratelli F . Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration. Clin Cancer Res. 2017; 23(16):4556-4568. PMC: 5599263. DOI: 10.1158/1078-0432.CCR-16-2821. View

Martens-Uzunova E, Bottcher R, Croce C, Jenster G, Visakorpi T, Calin G . Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2013; 65(6):1140-51. DOI: 10.1016/j.eururo.2013.12.003. View

Gandini S, Massi D, Mandala M . PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016; 100:88-98. DOI: 10.1016/j.critrevonc.2016.02.001. View

Jin W . Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. Cells. 2020; 9(1). PMC: 7017057. DOI: 10.3390/cells9010217. View

Peng W, Koirala P, Mo Y . LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017; 36(41):5661-5667. PMC: 6450570. DOI: 10.1038/onc.2017.184. View

Fatima R, Akhade V, Pal D, Rao S . Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015; 3:5. PMC: 4469312. View

Wang T, Zhao Y, Peng L, Chen N, Chen W, Lv Y . Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017; 66(11):1900-1911. PMC: 5739867. DOI: 10.1136/gutjnl-2016-313075. View

10.

Lenis A, Lec P, Chamie K, Mshs M . Bladder Cancer: A Review. JAMA. 2020; 324(19):1980-1991. DOI: 10.1001/jama.2020.17598. View

11.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

12.

Cao H, Liu Z, Huang P, Yue Y, Xi J . lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 2019; 23(3):1012-1021. DOI: 10.26355/eurrev_201902_16988. View

13.

Bunt S, Yang L, Sinha P, Clements V, Leips J, Ostrand-Rosenberg S . Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007; 67(20):10019-26. PMC: 4402704. DOI: 10.1158/0008-5472.CAN-07-2354. View

14.

Wang D, You D, Dong J, Liu T . Knockdown of long non-coding RNA LINC00518 inhibits cervical cancer proliferation and metastasis by modulating JAK/STAT3 signaling. Eur Rev Med Pharmacol Sci. 2019; 23(2):496-506. DOI: 10.26355/eurrev_201901_16861. View

15.

Ju Q, Zhao Y, Ma S, Li X, Zhang H, Zhang S . Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma. J Cancer Res Clin Oncol. 2020; 146(7):1711-1723. DOI: 10.1007/s00432-020-03224-8. View

16.

Li J, Meng H, Bai Y, Wang K . Regulation of lncRNA and Its Role in Cancer Metastasis. Oncol Res. 2016; 23(5):205-17. PMC: 7838649. DOI: 10.3727/096504016X14549667334007. View

17.

Ritch C, Velasquez M, Kwon D, Becerra M, Soodana-Prakash N, Atluri V . Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. J Urol. 2019; 203(3):505-511. DOI: 10.1097/JU.0000000000000593. View

18.

Cao Y, Tian T, Li W, Xu H, Zhan C, Wu X . Long non-coding RNA in bladder cancer. Clin Chim Acta. 2020; 503:113-121. DOI: 10.1016/j.cca.2020.01.008. View

19.

Inman B, Longo T, Ramalingam S, Harrison M . Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2016; 23(8):1886-1890. DOI: 10.1158/1078-0432.CCR-16-1417. View

20.

Maeser D, Gruener R, Huang R . oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021; 22(6). PMC: 8574972. DOI: 10.1093/bib/bbab260. View